

Financial Tear Sheet

Corporate Profile

- We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic human biology and disease.
- We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
- We are harnessing our foundational ability to characterize specialized human cells and to 3D bioprint functional tissues to create novel in vitro toxicology and liver disease modeling platforms.
- We are striving to change the face of medicine through clinical development of regenerative medicine therapies for treating disease and by enabling translational drug discovery.

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations &
 Corporate
 Communications
Phone: 858-224-1092
Email:
 skunszabo@organovo.com

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.11
Change (%)	▲ 0.04 (3.74%)
Volume	900,141
52 Week Low	\$0.90
Market Cap	\$127,857,875
Rolling EPS	-0.24
PE Ratio	0
Shares Outstanding	119,493,341
Data as of 02/22/19 12:38 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

02/20/19

Organovo Appoints New Board Member

02/07/19

Organovo Affirms Key Clinical Development Goals;
Company Reports Fiscal Third-Quarter 2019
Results

01/17/19

Organovo Announces Release Date for Fiscal Third-
Quarter 2019 Financial Results

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/21/19	4
02/21/19	4
02/21/19	4
02/21/19	4

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager